WallStSmart

Collegium Pharmaceutical Inc (COLL)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 1723% more annual revenue ($14.74B vs $808.21M). COLL leads profitability with a 5.9% profit margin vs -2.8%. VTRS earns a higher WallStSmart Score of 48/100 (D+).

COLL

Hold

48

out of 100

Grade: D+

Growth: 5.3Profit: 6.0Value: 7.0Quality: 4.0
Piotroski: 5/9Altman Z: 1.05

VTRS

Hold

48

out of 100

Grade: D+

Growth: 2.7Profit: 3.5Value: 4.3Quality: 5.0
Piotroski: 4/9Altman Z: 0.55
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

COLLUndervalued (+88.5%)

Margin of Safety

+88.5%

Fair Value

$391.37

Current Price

$23.04

$368.33 discount

UndervaluedFair: $391.37Overvalued
VTRSSignificantly Overvalued (-84.5%)

Margin of Safety

-84.5%

Fair Value

$8.74

Current Price

$17.10

$8.36 premium

UndervaluedFair: $8.74Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COLL1 strengths · Avg: 8.0/10
Price/BookValuation
2.4x8/10

Reasonable price relative to book value

VTRS1 strengths · Avg: 10.0/10
Price/BookValuation
1.4x10/10

Reasonable price relative to book value

Areas to Watch

COLL4 concerns · Avg: 2.5/10
Market CapQuality
$724.14M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
5.9%3/10

5.9% margin — thin

EPS GrowthGrowth
-46.6%2/10

Earnings declined 46.6%

Altman Z-ScoreHealth
1.052/10

Distress zone — elevated risk

VTRS4 concerns · Avg: 2.5/10
Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Return on EquityProfitability
-2.9%2/10

ROE of -2.9% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.552/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : COLL

The strongest argument for COLL centers on Price/Book.

Bull Case : VTRS

The strongest argument for VTRS centers on Price/Book. PEG of 1.05 suggests the stock is reasonably priced for its growth.

Bear Case : COLL

The primary concerns for COLL are Market Cap, Profit Margin, EPS Growth. Debt-to-equity of 2.75 is elevated, increasing financial risk.

Bear Case : VTRS

The primary concerns for VTRS are Revenue Growth, Return on Equity, EPS Growth.

Key Dynamics to Monitor

COLL profiles as a value stock while VTRS is a turnaround play — different risk/reward profiles.

VTRS carries more volatility with a beta of 0.88 — expect wider price swings.

COLL is growing revenue faster at 6.3% — sustainability is the question.

VTRS generates stronger free cash flow (329M), providing more financial flexibility.

Bottom Line

COLL scores higher overall (48/100 vs 48/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Collegium Pharmaceutical Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets pain management medications. The company is headquartered in Stoughton, Massachusetts.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?